PROGRAM OVERVIEW
Join us for a dynamic, expert-led broadcast exploring the latest clinical data for EXDENSUR, the first and only ultra-long-acting biologic for appropriate patients with asthma or chronic rhinosinusitis with nasal polyps (CRSwNP) given in just 2 doses a year. This unique session features a panel of leading specialists and clinical investigators from across multiple disciplines: Dr Eric Caplan (Allergy/Immunology), Dr Stella Cohen (Pulmonology), and Dr Joe Han (Otolaryngology), as they share their perspectives on the opportunity for EXDENSUR to change clinical practice. You will also have the opportunity to engage and ask the panel questions during the Q&A session.
PROGRAM OBJECTIVES
- Hear perspectives on how the multi-disciplinary panel navigates patient challenges when managing asthma or CRSwNP with a biologic
- Explore how EXDENSUR was designed for extended dosing in just 2 doses a year to help simplify biologic treatment
- Discuss the clinical data evaluating exacerbation reduction in patients with asthma with type 2 inflammation characterized by an eosinophilic phenotype who are on medium- to high-dose inhaled corticosteroids (ICS) plus a controller
- Review the clinical data evaluating nasal polyps size and obstruction in patients with inadequately controlled CRSwNP
Broadcast Schedule
The broadcast will be available at various times throughout the day and evening, depending on your time zone. Reference the chart below for a complete list of broadcast times.
This broadcast is available via webcast and teleconference at the times listed below.
Available via
Lunch Program: [Wednesday, January 28, 2026]
| EASTERN | CENTRAL | MOUNTAIN | PACIFIC |
|---|---|---|---|
| 12:15 PM | 11:15 AM | 10:15 AM | 9:15 AM |
| 1:15 PM | 12:15 PM | 11:15 AM | 10:15 AM |
| 2:15 PM | 1:15 PM | 12:15 PM | 11:15 AM |
| 3:15 PM | 2:15 PM | 1:15 PM | 12:15 PM |
Dinner Program: [Thursday, January 29, 2026]
| EASTERN | CENTRAL | MOUNTAIN | PACIFIC |
|---|---|---|---|
| 7:00 PM | 6:00 PM | 5:00 PM | 4:00 PM |
| 9:00 PM | 8:00 PM | 7:00 PM | 6:00 PM |
Intended Audience
This broadcast is intended for US healthcare professionals involved in the treatment of asthma and CRSwNP.
[Indications
- EXDENSUR is indicated for the add-on maintenance treatment of asthma in adult and pediatric patients aged 12 years and older with type 2 inflammation characterized by an eosinophilic phenotype on medium- to high-dose inhaled corticosteroids (ICS) plus another asthma controller. EXDENSUR is not indicated for the relief of acute bronchospasm or status asthmaticus.
- EXDENSUR is indicated as add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
Important Safety Information
Warnings and Precautions
Hypersensitivity Reactions Acute and delayed systemic reactions, including hypersensitivity reactions (such as urticaria and pruritus), have with EXDENSUR. These reactions generally occur within hours of administration, but some had a delayed onset (i.e., days). Clinical judgment must be used regarding readministration if hypersensitivity reaction occurs.
Asthma-Related Adverse Events or Exacerbations EXDENSUR must not be used to treat acute asthma symptoms or acute exacerbations. Asthma-related adverse events or exacerbations may occur during treatment with EXDENSUR. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with EXDENSUR.
Reduction of Maintenance Medication Dosage Abrupt discontinuation of background medications (including systemic and inhaled corticosteroids) after initiation of EXDENSUR therapy is not recommended. Reductions in the dosages of background medications, if appropriate, must be gradual and performed under the supervision of a physician.
Parasitic (Helminth) Infection Treat patients with pre-existing helminth infections before initiating therapy with EXDENSUR. If patients become infected while receiving EXDENSUR and do not respond to anti-helminth treatment, consider delaying EXDENSUR until the infection resolves.
Adverse Reactions: Most common adverse reactions (>1%) in patients were pruritus, administration-related systemic reactions, and injection site reactions.
USE IN SPECIFIC POPULATIONS The effect of EXDENSUR on human pregnancy is unknown. Monoclonal antibodies, such as depemokimab-xxx, are expected to be transported across the placenta in a linear fashion as the pregnancy progresses. EXDENSUR should be used during pregnancy only if the expected benefit to the mother justifies the potential risk to the fetus.
To report SUSPECTED ADVERSE REACTIONS, contact GSK at https://gsk.public.reportum.com or 1-888-825-5249 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
|
|
Trademarks are property of their respective owners. ©2025 GSK or licensor. PMUS-DEPEWCNT250020 October 2025 Produced in USA. |